Certified Global Research Member

Key Questions Answered

Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the key challenges in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major playersâ€™ financial performance.
Evaluate strategies adopted by major players.
Recommendations

Why Choose Market Research Future?

Vigorous research methodologies for specific market.
Knowledge partners across the globe
Large network of partner consultants.
Ever-increasing/ Escalating data base with quarterly monitoring of various markets
Trusted by fortune 500 companies/startups/ universities/organizations
Large database of 5000+ markets reports.
Effective and prompt pre- and post-sales support.

Renal Cancer Drug Companies

Renal cancer, or kidney cancer, is a type of cancer that originates in the kidneys. Companies involved in renal cancer drug development focus on researching, developing, and manufacturing pharmaceuticals for the treatment of renal cell carcinoma (RCC) and other forms of kidney cancer. These companies play a critical role in advancing therapeutic options for individuals diagnosed with renal cancer.

Renal Cancer Drug Key Companies

Latest Renal Cancer Drug Companies Update

Merck (MSD) FDA Priority Review granted for their sNDA for Welireg (a HIF-2α inhibitor) for previously treated RCC patients, with potential approval by January 17, 2024.Positive Phase III LITESPARK-005 trial results demonstrating Welireg's efficacy in extending progression-free survival (PFS) in advanced RCC patients.

Pfizer Expanded use of Bavencio (avelumab) with atezolizumab (Tecentriq) as first-line treatment for advanced RCC, as recommended by the National Comprehensive Cancer Network (NCCN) guidelines.

Invectys FDA Fast Track designation granted for their CAR-T therapy IVS-3001 for the treatment of RCC.

Bristol Myers Squibb Phase II clinical trial initiated for Nivolumab (Opdivo) in combination with Cabozantinib for treatment of papillary RCC.

List of Renal Cancer Drug Key Companies in the Market

Novartis AG (Switzerland)

Pfizer Inc. (US)

GlaxoSmithKline plc (UK)

Genentech Inc. (US)

Hoffmann-La Roche AG (Switzerland)

Cipla Limited (India)

Active Biotech AB (Sweden)

Amgen (US)

Bayer AG (Germany)

Bristol-Myers Squibb company (US)

Renal Cancer Drug Market Highlights:

Renal Cancer Drug Market Size

Renal Cancer Drug Market Trends

Renal Cancer Drug Market Analysis

Renal Cancer Drug Market Share

Renal Cancer Drug Market Highlights:

Renal Cancer Drug Market Trends

Renal Cancer Drug Market Analysis

Renal Cancer Drug Market Share

Renal Cancer Drug Companies

Leading companies partner with us for data-driven Insights

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
	Single User	$ 4,950
	Multiuser License	$ 5,950
	Enterprise User	$ 7,250
Compare Licenses

Tailored for You

Dedicated Research on any specifics segment or region.
Focused Research on specific players in the market.
Custom Report based only on your requirements.
Flexibility to add or subtract any chapter in the study.
Historic data from 2014 and forecasts outlook till 2040.
Flexibility of providing data/insights in formats (PDF, PPT, Excel).
Provide cross segmentation in applicable scenario/markets.